DCTH: Delcath Corp Consensus Target

Symbol and logo of brand Delcath Systems Inc (DCTH)

The price trend shown below demonstrates the dynamics of Delcath Systems, Inc. (DCTH), whose success is based on insurance provider recognition and physician training. The business relies on the expansion of the Hepzato system into US liver therapy clinics, where profitability stands at 27.25. Meanwhile, Delcath Systems, Inc. (DCTH) adheres to standard environmental regulations typical for the operation of modern research laboratories.

DCTH - delcath.com Analyst Consensus Forecast over the range 07/04/2022 - 11/11/2026
Original product of Delcath

The assessment of operational asset strength is based on aggregated expert expectations, where the analyst consensus on share value captures the balance of supply and demand through daily monitoring of target prices. For Delcath Systems, Inc. (DCTH), the trend of this indicator reflects market confidence in the successful commercialization of the hepatic chemoperfusion system, confirming the fundamental resilience of the business as it expands into US oncology centers.

Competing companies

beigene.com - Broker Consensus Forecast|Analyst Consensus Forecast HALO (Halozyme)|RVMD - Consensus Target|AAPG: Consensus Target|CG Oncology Therapeutics - Analyst Forecast Prices|URGN: Analyst Consensus Forecast|bicara.com - Fair Value Consensus|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast YMAB|Analyst Consensus Forecast Aura Corp (AURA)|Price Target Chart Candel Therapeutics, Inc. CADL|ARAY: Broker Consensus Forecast|SELLAS Life Sciences Group Inc. - Analyst Consensus Forecast|Actuate Therapeutics Inc. (ACTU) - Consensus Target|CTOR: Analyst Consensus Forecast|Average Forecast Price TuHURA Biosciences (HURA)|Price Target Chart Protara Therapeutics|FATE: Fair Value Consensus|Consensus Target WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Fair Value Consensus|Analyst Consensus Forecast CSBR (Champions Oncology, Inc.)|XBIT - Consensus Target|CVM: Consensus Target|OSTX - Analyst Consensus Forecast|Radiopharm Theranostics Limited (RADX) - Price Target Chart|Artiva Biotherapeutics - Fair Value Consensus|ANL (Adlai Nortye Ltd) - Analyst Consensus Forecast|Average Forecast Price Veru Corporation VERU|Analyst Consensus Forecast TPST|xiliotx.com - Broker Consensus Forecast|Analyst Consensus Forecast RENB (Renovaro)|Mural Oncology PLC (MURA) - Average Forecast Price|KAPA - Price Target Chart|OKUR: Price Target Chart|GDTC: Analyst Consensus Forecast|Consensus Target Curis|APLM (Apollomics Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Tharimmune Inc|Consensus Target ADVB (Advanced Biomed Inc)|Analyst Forecast Prices GNPX|Analyst Consensus Forecast CLDI (Calidi Biotherapeutics, Inc.)|Fair Value Consensus SBFM|XBIO: Consensus Target|Fair Value Consensus SLRX (Salarius Pharmaceuticals Inc)|Purple Biotech Corp (PPBT) - Price Target Chart|AONC - Analyst Median Target|Consensus Target BGNE|Average Forecast Price checkpointtx.com CKPT|Price Target Chart Elevation Oncology, Inc. (ELEV)|Analyst Median Target icadmed.com|Ikena Oncology - Consensus Target|Analyst Forecast Prices NTBL (Notable Labs Corp)|Viracta - Analyst Consensus Forecast|Average Forecast Price morphosys.com|NAYA Biosciences Inc. (NAYA) - Price Target Chart|Consensus Target Ascentage Pharma Group International